medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2004; 3 (4)


Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C

Soza A, Arrese M, González R, Alvarez M, Pérez RM, Cortés P, Patillo A, Riquelme A, Glasinovic JC

Idioma: Ingles.
Referencias bibliográficas: 25
Paginas: 146-151
Archivo PDF: 57.33 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.

  2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  3. Armas-Merino R, Wolff C, Soto R, Jiron MI, Parraguez A. [Hepatitis C virus and resulting diseases]. Rev Med Chil 1999; 127: 1240-1254.

  4. Schmunis GA, Zicker F, Pinheiro F, Brandling-Bennett D. Risk for transfusion-transmitted infectious diseases in Central and South America. Emerg Infect Dis 1998; 4: 5-11.

  5. Ministerio de Salud. Chile. Situación de la Hepatitis B, D y C en Chile, 1997. http://epi.minsal.cl/epi/html/public/hepat/situacionhepatitisbc.htm 1997.

  6. Muñoz G, Velasco M, Thiers V, Hurtado C, Brahm J, Larrondo-Lillo M, Guglielmetti A, et al. [Prevalence and genotypes of hepatitis C virus in blood donors and in patients with chronic liver disease and hepatocarcinoma in a Chilean population]. Rev Med Chil 1998; 126: 1035-1042.

  7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.

  8. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.

  9. Velasco M, Hurtado C, Brahm J. [Anti-hepatitis C viral antibodies in different pathological entities in Chile]. Rev Med Chil 1990; 118: 895-896.

  10. Rodriguez MI, Estay R, Soto JR, Wolff C, Plubins L, Child R, Armas R. [Prevalence of hepatitis C virus antibodies in a hemodialysis unit]. Rev Med Chil 1993; 121: 152-155.

  11. Vega I, Leon A, Zolezzi P, Ibarra H, Faundez C, Montecinos J. [Hepatitis C virus in a group of hematological and oncohematological patients]. Rev Med Chil 2001; 129: 18-22.

  12. Ibarra H, Riedemann S, Siegel F, Toledo C, Reinhardt G. [Acute hepatitis caused by virus A, E and non A-E in Chilean adults]. Rev Med Chil 2001; 129: 523-530.

  13. Velasco M, Brahm J, Katz R. [Long term follow-up of patients with chronic hepatitis due to hepatitis C virus]. Rev Med Chil 1994; 122: 1271-1275.

  14. Vega I, Colina R, Garcia L, Uriarte R, Mogdasy C, Cristina J. Diversification of hepatitis C viruses in South America reveals a novel genetic lineage. Arch Virol 2001; 146: 1623-1629.

  15. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.

  16. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26: 485-490.

  17. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.

  18. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695.

  19. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91-96.

  20. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233.

  21. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-870.

  22. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-587.

  23. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.

  24. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.

  25. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.




2020     |     www.medigraphic.com